Media headlines about Pluristem Therapeutics (NASDAQ:PSTI) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pluristem Therapeutics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.9468341155596 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the headlines that may have effected Accern’s rankings:
- Pluristem’s PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study (markets.financialcontent.com)
- Critical Comparison: GenVec (GNVC) and Pluristem Therapeutics (PSTI) (americanbankingnews.com)
- FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study (finance.yahoo.com)
- Pluristem Therapeutics (PSTI) versus ACADIA Pharmaceuticals (ACAD) Financial Contrast (americanbankingnews.com)
A number of equities analysts have commented on PSTI shares. HC Wainwright restated a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research note on Thursday, November 9th. Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 1st. Seaport Global Securities restated a “buy” rating and issued a $5.00 target price on shares of Pluristem Therapeutics in a research note on Friday, October 6th. Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. Finally, ValuEngine upgraded Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $3.83.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at $1.62 on Friday. Pluristem Therapeutics has a twelve month low of $1.04 and a twelve month high of $2.12.
Pluristem Therapeutics (NASDAQ:PSTI) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08). sell-side analysts anticipate that Pluristem Therapeutics will post -0.34 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://ledgergazette.com/2018/01/13/pluristem-therapeutics-psti-receives-news-impact-score-of-0-12.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.